AbbVie Inc.
ABBVNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B |
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 |
| Shares out. | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.48B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 24.6%
- Net margin
- 6.9%
- Return on equity
- −129.2%
- Return on assets
- 3.2%
- Return on capital (ROCE)
- 16.6%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-1.85
- Revenue growth (YoY)
- 8.6%
- Net income growth (YoY)
- −1.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −11.1%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 good- Negative shareholder equity
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- EMBLAVEOFeb 7, 2025
- RINVOQ LQApr 26, 2024
- VUITYOct 28, 2021
- MAVYRETJun 10, 2021
- ORIAHNN (COPACKAGED)May 29, 2020
- DURYSTAMar 4, 2020
- RINVOQAug 16, 2019
- ORILISSAJul 23, 2018
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2017-10-27A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
- Phase 3Active Not Recruitingreadout ~2020-10-08A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- Phase 1Active Not Recruitingreadout ~2024-02-07A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
- Phase 3Active Not Recruitingreadout ~2025-09-23A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
- Phase 1Not Yet Recruitingreadout ~2026-02A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
- Phase 1Active Not Recruitingreadout ~2026-03A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
- Phase 1Recruitingreadout ~2026-03-21A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- Phase 1Active Not Recruitingreadout ~2026-05An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Falk Thomas JDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Waddell Frederick HDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Roberts Rebecca BDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Rapp Edward JDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Quaggin Susan EDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Meyer Melody BDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Hart Brett JDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Freyman Thomas CDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
| Davis Jennifer L.Director | May 8, 2026 | Grant | 1,118 | $0.00 |
| Burnside William H.L.Director | May 8, 2026 | Grant | 1,118 | $0.00 |
| Austin Roxanne SDirector | May 8, 2026 | Grant | 1,118 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 22.6M | 4.0 | +8.1% |
| Apr 30, 2026 | 20.9M | 2.7 | -4.3% |
| Apr 15, 2026 | 21.8M | 3.7 | +8.6% |
| Mar 31, 2026 | 20.1M | 2.5 | -19.9% |
| Mar 13, 2026 | 25.1M | 3.7 | +15.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 12, 2026
- Results of operationsApr 29, 2026
- Results of operationsApr 3, 2026
- Other material eventMar 4, 2026
- Other material eventFeb 26, 2026
- Results of operationsFeb 4, 2026
- Results of operationsJan 7, 2026
- Results of operationsOct 31, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from Abbott LaboratoriesABT · Dec 31, 2012
From the spin-off filings we track. Follow a company to walk its own history.